Overview
OTLK market data
Price History
OTLK price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.79 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.63 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,507.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.16 – $3.39 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $163.2M · P/B 31.58 · P/S 383.96.
Company News
BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price TargetBenzinga · Aug 14, 2026, 5:19 PM
12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · Aug 14, 2026, 5:06 PM
Outlook Therapeutics shares are trading lower after the company reported worse-than-expected Q3 sales results.Benzinga · Aug 14, 2026, 3:04 PM
Transcript: Outlook Therapeutics Q3 2026 Earnings Conference CallBenzinga · Aug 14, 2026, 1:25 PM
8-K filing — Outlook Therapeutics, Inc. (OTLK)SEC EDGAR · Aug 14, 2026, 12:36 PM
Outlook Therapeutics Q3 Adj. EPS $(0.09), Inline, Sales $9.000K Miss $5.300M EstimateBenzinga · Aug 14, 2026, 11:59 AM
S&P 500 Hits New Record High Following PPI Data: Investor Sentiment Improves, Fear Index Remains In ‘Greed’ ZoneBenzinga · Aug 14, 2026, 6:45 AM
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsBenzinga · Aug 14, 2026, 5:30 AM
Outlook Therapeutics shares are trading lower after the company announced the pricing of its $55 million offering of 55,555,556 shares and warrants at $0.99 combined price per share.Benzinga · Aug 13, 2026, 1:27 PM
Reported Earlier, Outlook Therapeutics Prices $55.0M Offering Of 55,555,556 Shares And Warrants At $0.99 Combined Price Per ShareBenzinga · Aug 13, 2026, 7:10 AM